news article, page-2

I suspect we may see numerous media reports in the next few weeks about the heart pump, a lot of human interest lies within this story and one would assume it is why the company has such a vast number of shareholders for its size. The device weighs in at only one third of the US made Abiocor pump which is now in common use to an FDA limit of 4000 per annum, it is also a third generation pump, design wise. Last year the US biotech venture capitalists evaluated this design as having the best prospects they has seen for success, the sheer simplicity of design with a single moving part impressed the medicos greatly.

Media reports, you bet, they have only just begun